Split History
ETFs Holding PTIX »    PTIX Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Protagenic Therapeutic is a development stage biopharmaceutical company focusing on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Co.'s proprietary compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Additionally, Co. is engaged in the research and development of follow-on compounds in the TCAP family. Co. is performing clinical trials to obtain Food and Drug Administration approval and commercialization of its product. According to our PTIX split history records, Protagenic Therapeutics has had 2 splits.
PTIX split history picture
Protagenic Therapeutics (PTIX) has 2 splits in our PTIX split history database. The first split for PTIX took place on September 16, 1997. This was a 3 for 2 split, meaning for each 2 shares of PTIX owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. PTIX's second split took place on September 02, 1999. This was a 3 for 2 split, meaning for each 2 shares of PTIX owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as Protagenic Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the PTIX split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Protagenic Therapeutics shares, starting with a $10,000 purchase of PTIX, presented on a split-history-adjusted basis factoring in the complete PTIX split history. PTIX split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/27/2021
End date: 01/27/2023
Start price/share: $2.26
End price/share: $0.59
Dividends collected/share: $0.00
Total return: -73.88%
Average Annual Total Return: -53.50%
Starting investment: $10,000.00
Ending investment: $2,611.58
Years: 1.75
Date Ratio
09/16/19973 for 2
09/02/19993 for 2
PTIX is categorized under the Technology sector; below are some other companies in the same sector that also have a history of stock splits:

QADB Split History
QCOM Split History
QLGC Split History
QRVO Split History
QSII Split History
QTM Split History
QUIK Split History
RADA Split History
RBCN Split History
RCN Split History

Email EnvelopeFree PTIX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
OpGen, Inc. (OPGN)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

PTIX Insider Buying

PTIX Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.